Jeremy Aboagye

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Veterinary Medicine, Immunology, Immunization +16

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer et al. · Nature Medicine · 2020 · 643 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold et al. · Nature Medicine · 2020 · 340 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12